x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: How Biotech Gets Built

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

01:11:59

Video Episode 67: Aoife Brennan, President and CEO of...

Few & Far Between: How Biotech Gets Built ·

2026/01/07

Let's kick off 2026 with the first Biorasi podcast episode of the year! How do you get "Biotech Vision" to see the complete picture of your place in the industry? Find out in the latest episode of the Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes guest Aoife Brennan, President and CEO of Climb Bio. We'll be discussing how to leverage science and strategy, the differences between CEOs and CMOs, and how hiring an

en

00:43:27

Episode 66: Mark Abelson, Founder of Ora Clinical

Few & Far Between: How Biotech Gets Built ·

2025/12/16

Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer. We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location. Listen today!

en

00:43:27

Episode 66: Mark Abelson, Founder of Ora Clinical

Few & Far Between: How Biotech Gets Built ·

2025/12/16

Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer. We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location. Listen today!

en

01:06:51

Video Episode 65 - Amit Etkin, Founder and CEO of...

Few & Far Between: How Biotech Gets Built ·

2025/11/24

With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etkin, Founder and CEO of Alto Neuroscience and Professor of Psychiatry at Stanford University School of Medicine. We’ll be discussing placebos in psychiatry, using biomarkers for patient outcomes, and what you can and can’t do in academia and biotech. Watch it today!

en

01:06:51

Video Episode 65 - Amit Etkin, Founder and CEO of...

Few & Far Between: How Biotech Gets Built ·

2025/11/24

With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etkin, Founder and CEO of Alto Neuroscience and Professor of Psychiatry at Stanford University School of Medicine. We’ll be discussing placebos in psychiatry, using biomarkers for patient outcomes, and what you can and can’t do in academia and biotech. Watch it today!

en

00:47:30

Video Episode 64 - Professor Justin Stebbing

Few & Far Between: How Biotech Gets Built ·

2025/11/11

Will GLP-1's one day replace our morning coffee? Find out in a special video episode of the Few & Far Between podcast! Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype. Let's start the podcast!

en

00:47:30

Video Episode 64 - Professor Justin Stebbing

Few & Far Between: How Biotech Gets Built ·

2025/11/11

Will GLP-1's one day replace our morning coffee? Find out in a special video episode of the Few & Far Between podcast! Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype. Let's start the podcast!

en

01:01:16

Video Episode 63 - Bruce Leuchter, MD, President and...

Few & Far Between: How Biotech Gets Built ·

2025/10/28

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien. Today, we welcome guest Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences. We’ll be covering a myriad of biotech topics, from “business athletes” to the role of the operating company in the drug development industry. We’ll also be premiering our lightning round - quick

en

01:01:16

Video Episode 63 - Bruce Leuchter, MD, President and...

Few & Far Between: How Biotech Gets Built ·

2025/10/28

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien. Today, we welcome guest Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences. We’ll be covering a myriad of biotech topics, from “business athletes” to the role of the operating company in the drug development industry. We’ll also be premiering our lightning round - quick

en

00:44:15

Episode 62: Ken Suzuki, Chief Marketing Officer at...

Few & Far Between: How Biotech Gets Built ·

2025/10/22

When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and

en

00:44:15

Episode 62: Ken Suzuki, Chief Marketing Officer at...

Few & Far Between: How Biotech Gets Built ·

2025/10/22

When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and

en

00:45:18

Episode 61: Woody Bryan, President and CEO of Revolo...

Few & Far Between: How Biotech Gets Built ·

2025/10/01

Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry. Let's start the podcast!

en

00:45:18

Episode 61: Woody Bryan, President and CEO of Revolo...

Few & Far Between: How Biotech Gets Built ·

2025/10/01

Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry. Let's start the podcast!

en

00:42:11

Episode 60: Part Two: Yochi Slonim, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2025/09/17

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology. Okay, let's start the podcast!

en

00:42:11

Episode 60: Part Two: Yochi Slonim, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2025/09/17

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology. Okay, let's start the podcast!

en

00:43:41

Episode 59, Part One: Yochi Slonim, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2025/09/03

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast!

en

00:43:41

Episode 59, Part One: Yochi Slonim, Co-Founder and...

Few & Far Between: How Biotech Gets Built ·

2025/09/03

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast!

en

00:44:43

Episode 58: Jerry McLaughlin, CEO and Board Member at...

Few & Far Between: How Biotech Gets Built ·

2025/08/14

How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!

en

00:44:43

Episode 58: Jerry McLaughlin, CEO and Board Member at...

Few & Far Between: How Biotech Gets Built ·

2025/08/14

How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!

en

00:44:53

Episode 57: Jim Brown, DVM, President and CEO of...

Few & Far Between: How Biotech Gets Built ·

2025/07/22

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today!

en

121 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter